“It is an honor to be named as one of the ‘Fierce 15,’ an award that recognizes our employees, our clinical collaborators and patients for the advancements we’re making in the field of cancer immunotherapy,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “This has been a year of tremendous progress at the company on a number of fronts, with exciting new data generated in our pancreatic cancer and mesothelioma trials, a new collaboration with Janssen Biotech, Inc. and completion of a $55 million venture round.
